Chandra Bhagat Pharma Limited AGM Results Pending

Chandra Bhagat Pharma Limited proposed the issuance of 66,00,000 convertible warrants at its 23rd AGM held on September 1, 2026.

Reader Takeaway: Shareholders should track voting results on the proposed warrant issuance, which signals potential equity-linked capital expansion.

What just happened

At its 23rd Annual General Meeting held in Mumbai, Chandra Bhagat Pharma Limited placed several key agenda items before its shareholders. These included the adoption of the FY26 annual accounts and the re-appointment of Mr. Pranav Hemant Bhagat as a director. The most significant proposal is the issuance of up to 6,600,000 convertible warrants on a preferential basis to both promoter and non-promoter entities. The management also confirmed that the Statutory Auditors' report for the financial year ended March 31, 2026, contains no qualifications or negative observations.

Voting Process

As a company listed on the BSE SME platform, Chandra Bhagat Pharma utilized physical polling and ballot papers for the voting process, following an exemption from e-voting requirements. Shareholders who held shares as of the cut-off date of August 25, 2026, were eligible to participate. The formal results of these votes will be disclosed following the receipt of the Scrutinizer's Report.

Why this matters

The potential issuance of 66 lakh warrants is a critical development for existing shareholders. If approved, the conversion of these warrants into equity could provide the company with fresh cash for future operations, though it also implies potential dilution for current stakeholders. Investors should look for the upcoming filing to confirm if these resolutions passed with the necessary majority.

What to track next

Watch for the official announcement regarding the voting results, which is expected within two working days of the Scrutinizer's report. This filing will clarify if the company has received the green light to proceed with the proposed capital restructuring.